Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

BACKGROUND: Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib. To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patie...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Shaw, A. T., Varghese, A. M., Solomon, B. J., Costa, D. B., Novello, S., Mino-Kenudson, M., Awad, M. M., Engelman, J. A., Riely, G. J., Monica, V., Yeap, B. Y., Scagliotti, G. V.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2013
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3525134/
https://ncbi.nlm.nih.gov/pubmed/22887466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds242
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg